CTCBIO

β-mannanase feed enzyme fermented from a Bacillus strain (WL-1) that breaks down mannose components abundant in soybeans but hard to use; registered in the U.S. in 2016 and exported to more than 30 countries as of 2023.

Bacteriophage feed additives for pigs, poultry and cattle that selectively kill specific pathogenic bacteria; launched in 2010 and exported to more than 15 countries as of 2023.

ODM and CMO of powders, tablets, hard capsules and oral dissolving films (ODF), based on formulation technologies such as microencapsulation, taste and odour masking, enteric coating, solubilisation and controlled release.

Operates four plants in Korea: Plant 1 in Hwaseong (health functional foods and animal-health additives), Plant 2 in Hongcheon (animal injectables and liquids), Plant 3 in Ansan (a KGMP plant dedicated to finished ODF products) and Plant 4 in Gimhae, completed in 1999.

At BASF's APAC Distributor Exchange 2026, received two awards, 2025 Record Sales Growth and 2025 Long-term Partnership, for sales growth in the Korean market over the past year.

Reported first-half 2026 standalone revenue of KRW 62.2 billion, operating profit of KRW 9.0 billion and net profit of KRW 5.8 billion, with all three divisions (animal health, human pharmaceuticals and raw materials) profitable.

Took part in SIAVS 2026 in São Paulo, Brazil, South America's largest livestock show, presenting its beta-mannanase and bacteriophage technologies and products such as CTCZyme, and discussed supply and cooperation with local feed and additive companies.